Collaborators Launch Trial Of MSC Treatment For Rare Infant Heart Conditions.
MIAMI, Fla., February 27, 2018 -- The University of Maryland Medical Center in Baltimore has launched a Phase 1 clinical trial of a mesenchymal stem cell-based treatment for infants with hypoplastic left heart syndrome (HLHS).
The cells used in the trial are provided by Florida-based stem cell company Longeveron.
Hypoplastic left heart syndrome is a rare and often fatal heart condition caused by an underdeveloped heart.
One aim of the clinical trial is to determine if the stem cell treatment can improve the ventricular function of the heart in affected infants.
"The hope is the stem cell therapy available through this clinical trial will be a game-changer for these infants, an effective way to improve their outcomes and allow them to live longer lives," said Sunjay Kaushal of the University of Maryland. Kaushal performed the procedure.
The study--"Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart Syndrome (ELPIS)"--is an open-label clinical trial enrolling 30 infants with HLHS overseen by Longeveron, a Miami-based regenerative medicine company, the University of Maryland, and Johns Hopkins University.
The Maryland Stem Cell Research Fund (MSCRF) provided a $750,000 grant to support the stem cell research.
The grant was part of the MSCRF's Accelerating Cure initiative. The Maryland Governor and the state's General Assembly established the MSCRF through the Maryland Stem Cell Research Act of 2006 to accelerate research using human stem cells and advance medical treatment.
Longeveron's research focus areas include Alzheimer's disease, aging frailty, and metabolic syndrome.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||In The Clinic|
|Publication:||Stem Cell Research News|
|Date:||Mar 12, 2018|
|Previous Article:||Wellness Protocol Clipical Trial To Begin In Mexico.|
|Next Article:||Dosing Of Second Cohort In Parkinson's Trial Completed.|